Fructose infusions have been safely applied to directly support metabolic activity in skeletal muscle cells (which endogenously express GLUT5) during endurance events that deplete plasma glucose.37 Parenteral routes bypass the post-prandial conversion to lactate that occurs in splanchnic organs.38,39,40 Clinically, we note that KHK inhibitors could be repurposed to raise plasma fructose in a combinatorial manner with GLUT5-expressing CAR-Ts against cancer. The gene discussed is SLC2A5; the disease is cancer.